Waypoint Bio
Business Services · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
430 E 29th St, New York City, New York, ...Website
www.waypointbio.comRevenue
$5.1 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Waypoint Bio
Waypoint Bio is developing AI-designed therapeutics using a platform that integrates artificial intelligence, computer vision, and spatial pooled screening. The company's lead program is an in vivo CAR T asset paired with a proprietary next-generation lentiviral vector, with clinical entry in China expected in late 2026. Waypoint is based in New York and is extending its platform into biologics and additional therapeutic areas.Explore more
Waypoint Bio Org Chart
CK
Scientist
MS
Senior Scientist
RS
Senior Scientist
LH
Senior Scientist
TW
Scientist
JM
Spatial Biology Intern
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Waypoint Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Waypoint Bio has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Waypoint Bio
Website visits: Recent activity has been detected on your website
Check out if Waypoint Bio is spiking on competitors!
Earning: See what the market has to say on Waypoint Bio recently announced quarterly report
Product Launch: Get notified when Waypoint Bio launches new products
Waypoint Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Waypoint Bio had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Waypoint Bio has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Waypoint Bio
Compare insights from companies similar to Waypoint Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Waypoint Bio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Waypoint Bio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Waypoint Bio.
Waypoint Bio financials insights
Gather financial insights about Waypoint Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Angel/Seed
$14.5M
2026
Series A
$20M
Waypoint Bio Tech Stack
A closer look at the technologies used by Waypoint Bio
Waypoint Bio News & Media
Waypoint Bio Appoints Meta NeuroAI Pioneer Patrick Kaifosh as Chief Technology Officer
Acclaimed Neurotechnology Leader to Advance Waypoint Bio’s AI-driven Cell Therapy Platform and Accelerate In Vivo CAR T DevelopmentWaypoint Bio Launches with $14.5M to Turbocharge Drug Discovery using in vivo Spatial Pooled Screening Technology
NEW YORK--(BUSINESS WIRE)--Waypoint Bio (aka “Waypoint”), a biotechnology company pioneering novel cell therapies for solid tumors using in vivo spatial pooled screening technology, today announced $14.5 million in seed funding led by Hummingbird Ventures with participation from other institutional investors, including Recode Ventures and pre-seed lead Fifty Years. The FDA recently approved the first ever cell therapy for solid tumors, yet innovation in this area has been slow given the challen
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Waypoint Bio
Sign Up For FreeTo access detailed company insights
Waypoint Bio is developing AI-designed therapeutics using a platform that integrates artificial intelligence, computer vision, and spatial pooled screening. The company's lead program is an in vivo CAR T asset paired with a proprietary next-generation lentiviral vector, with clinical entry in China expected in late 2026. Waypoint is based in New Yo... Read More
